Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors. David brings with him an impressive career of more than 25 years in pharma and biotech business development and strategy. His previous roles include Head of Global Business Development at Shire and business development and commercial positions at Glaxo Wellcome and Novo Nordisk. David has a degree in Pharmacy and he also serves on the Boards of Orexo AB and HRA Pharma Ltd.
Please review the full text press release by clicking here: pdf version of the press release